Kementerian Kesehatan Republik Indonesia Penilaian Teknologi Kesehatan

Edoksaban untuk pencegahan stroke pada fibrilasi atrium nonvalvular

Penilaian teknologi kesehatan PTK-B01AF03 Draf untuk telaah Diperbarui 12 Juni 2026

1. Latar belakang klinis

Gambaran penyakit

Uraian berikut tersedia dalam bahasa Inggris.

Non-valvular atrial fibrillation (NVAF) is the most common sustained cardiac arrhythmia, characterised by rapid, disorganised atrial electrical activity, loss of effective atrial mechanical contraction, and an irregularly irregular ventricular response. Stasis of blood within the fibrillating left atrium and left atrial appendage promotes thrombus formation; embolisation of these thrombi to the cerebral circulation produces cardioembolic ischaemic stroke, which is typically larger, more disabling and more often fatal than non-cardioembolic stroke. Atrial fibrillation independently increases ischaemic stroke risk roughly four- to five-fold and accounts for a substantial share of strokes in older adults (PMC11850931). NVAF, the indication addressed here, excludes moderate-to-severe mitral stenosis and mechanical prosthetic valves. Because thromboembolic risk is largely modifiable through oral anticoagulation, stroke prevention is the central therapeutic objective in NVAF and the indication modelled here for edoxaban 60 mg once daily (Giugliano 2013; 2024 ESC AF Guidelines).

Epidemiologi

Uraian berikut tersedia dalam bahasa Inggris.

Globally, the Global Burden of Disease Study 2021 estimated 52.55 million prevalent cases of atrial fibrillation/atrial flutter (52,552,045; age-standardised prevalence 620.5 per 100,000), about 4.48 million incident cases, roughly 8.36 million DALYs and 0.34 million deaths annually, with absolute prevalence nearly doubling from 22.2 million in 1990 (an increase of approximately 136%) and continuing to grow (GBD 2021; PMC12133759). Indonesia lacks a nationally representative population prevalence: Riskesdas does not directly measure AF, though it documented rising self-reported stroke prevalence, from 7.0 per 1,000 in 2013 to 10.9 per 1,000 in 2018 (Riskesdas 2018), and stroke is among Indonesia's leading causes of death. The best Indonesian AF estimates are hospital-based: a multicentre tertiary-hospital smartphone-screening study found AF prevalence of approximately 3.2-3.5% (Yuniadi et al., J Arrhythm 2024; PMC11474569), and AF was detected in around 10.8% of ischaemic-stroke admissions (16 of 148; PMC11850931). These figures imply a large, under-detected and under-anticoagulated AF population in Indonesia.

Terapi standar saat ini

Uraian berikut tersedia dalam bahasa Inggris.

The contemporary standard of care for stroke prevention in NVAF is risk-stratified oral anticoagulation guided by the CHA2DS2-VASc (now CHA2DS2-VA) score, with bleeding-risk assessment before initiation. Historically this meant warfarin titrated to an INR of 2.0-3.0; even in the controlled ENGAGE AF-TIMI 48 trial the warfarin arm achieved a median TTR of only 68.4%, illustrating real-world control difficulty (Giugliano 2013). Direct oral anticoagulants (DOACs: apixaban, dabigatran, edoxaban, rivaroxaban) are now preferred over warfarin in eligible patients per the 2024 ESC/EACTS guidelines, except in mechanical valves and moderate-to-severe mitral stenosis where warfarin remains mandatory. In Indonesia, warfarin remains the most accessible and affordable agent and is widely used, but its monitoring burden, interactions and bleeding risk limit effective protection. Indonesian PERKI/InaHRS guidance on NVAF endorses DOACs over warfarin and antiplatelet therapy, though DOAC acquisition cost constrains equitable access under JKN (PERKI/InaHRS NVAF Guideline; 2024 ESC AF Guidelines).

Status regulasi dan penjaminan

Uraian berikut tersedia dalam bahasa Inggris.

Edoxaban (Savaysa/Lixiana, Daiichi Sankyo) received US FDA approval on 8 January 2015 for stroke prevention in NVAF and for VTE, based on ENGAGE AF-TIMI 48, and European Commission marketing authorisation (Lixiana) in 2015 following a positive CHMP opinion. NICE recommended edoxaban for preventing stroke and systemic embolism in adults with NVAF and at least one risk factor in technology appraisal TA355 (23 September 2015). In Indonesia, Lixiana (edoxaban) is registered with BPOM and marketed by PT Kalbe Farma in 15 mg, 30 mg and 60 mg tablets (registration series DKI1808900417, e.g. B1 for the 30 mg and C1 for the 60 mg strength). National reimbursement status warrants verification: the current Formularium Nasional was established by KMK HK.01.07/MENKES/1199/2025; DOAC inclusion and any restriction criteria should be confirmed directly against the live e-Fornas listing (e-fornas.kemkes.go.id) before any reimbursement assumption.

2. Hasil kasus dasar

StrategiBiaya terdiskontoQALY terdiskontoTahun hidup
Edoksaban 60 mg sekali sehariRp 48,4 juta9,65918,41
warfarin dengan target INR 2,0 sampai 3,0Rp 41,7 juta8,84116,75
SelisihRp 6,7 juta0,818-

3. Analisis probabilistik

Bidang efektivitas biaya. Setiap titik adalah satu simulasi probabilistik. Titik di bawah sumbu nol berarti intervensi menurunkan biaya.
-5051015200,000,501,001,50Tambahan tahun hidup berkualitas per pasien (QALY)Tambahan biaya per pasien (juta rupiah)1 kali PDB per kapita3 kali PDB per kapita
  • Simulasi probabilistik (500 sampel)
  • Kasus dasar
Kurva penerimaan. Peluang intervensi hemat biaya pada berbagai ambang kesediaan membayar.
020406080100050100150200250Ambang kesediaan membayar (juta rupiah per QALY)Peluang hemat biaya (%)75 juta225 juta100,0%

4. Analisis sensitivitas

Analisis sensitivitas satu arah. Sepuluh parameter dengan pengaruh terbesar terhadap manfaat moneter bersih.
-40-2002040interventions warfarin inr target 2 3 transition rate multipliers well on anticoagulation to dead other causeinterventions warfarin inr target ...interventions edoxaban 60mg OD transition rate multipliers well on anticoagulation to dead other causeinterventions edoxaban 60mg OD tra...interventions edoxaban 60mg OD transition rate multipliers well on anticoagulation to intracranial haemorrhageinterventions edoxaban 60mg OD tra...interventions warfarin inr target 2 3 transition rate multipliers well on anticoagulation to major bleedinterventions warfarin inr target ...interventions warfarin inr target 2 3 transition rate multipliers well on anticoagulation to intracranial haemorrhageinterventions warfarin inr target ...transition rates annual well on anticoagulation to intracranial haemorrhagetransition rates annual well on an...interventions edoxaban 60mg OD transition rate multipliers well on anticoagulation to major bleedinterventions edoxaban 60mg OD tra...transition rates annual well on anticoagulation to dead other causetransition rates annual well on an...utility values well on anticoagulationutility values well on anticoagula...interventions edoxaban 60mg OD drug cost idr per courseinterventions edoxaban 60mg OD dru...Perubahan manfaat moneter bersih per pasien (juta rupiah)Parameter
  • Parameter pada nilai rendah
  • Parameter pada nilai tinggi

5. Analisis skenario

SkenarioSelisih QALYSelisih biayaRasio per QALY
Base case (30 yr)0,818Rp 6,7 jutaRp 8,2 juta
5-year horizon0,053Rp 6,9 jutaRp 129,2 juta
10-year horizon0,197Rp 5,5 jutaRp 27,8 juta
20-year horizon0,544Rp 5,2 jutaRp 9,6 juta
0% discount rate1,372Rp 8,1 jutaRp 5,9 juta
5% discount rate0,600Rp 6,3 jutaRp 10,4 juta
Poor real-world INR control (warfarin stroke x1.3)0,826Rp 6,8 jutaRp 8,3 juta
Edoxaban at full retail price (~Rp14.6M/yr)0,818Rp 10,2 jutaRp 12,4 juta

6. Validasi model

Keseimbangan massa kohort terpenuhi pada seluruh siklus (simpangan terbesar 0,0010%).

7. Penyesuaian untuk Indonesia

Uraian berikut tersedia dalam bahasa Inggris.

  • NICE TA355 (2015) recommends edoxaban as an option for preventing stroke and systemic embolism in NVAF with 1+ risk factor, judged cost-effective vs warfarin (committee ICER GBP 16,000-22,100/QALY).
  • Indonesia base case compares edoxaban with warfarin because warfarin is the pragmatic BPJS baseline and DOAC access is cost-constrained under JKN.
  • Lower real-world INR control across many kabupaten (TTR well below ENGAGE 68.4%) would raise warfarin event rates and improve edoxaban's relative value; tested in the poor-INR-control scenario.
  • Budget impact may dominate affordability: NVAF prevalence rises steeply with age and anticoagulation is lifelong; eligible population is large and under-treated.
  • Confirm Fornas/e-Fornas listing and any restriction criteria (KMK HK.01.07/MENKES/1199/2025) and BPOM registration (Lixiana 15/30/60 mg, PT Kalbe Farma) before reimbursement interpretation.
  • Threshold uses 1x and 3x GDP proxy only; InaHTAC may apply different decision rules.